Clinical Trial

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a Prospective, Single-arm, Phase 2 clinical trial. The purpose of this study is to find out if taking Utidelone Capsules together with Fruquintinib Capsules is safe and works well for people with platinum-resistant ovarian cancer . Researchers will look at the Objective Response Rate, Progression-Free Survival, Overall Survival, safety, and any side effects.
Trial Details
NCT Number NCT06973421
Lead Sponsor Fudan University
Conditions Platinum Resistant Ovarian Cancer
Enrollment 35 participants
Start Date 2025-07-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-15